LL-37 Dosing Protocol: Cycling, Frequency & Best Practices

Introduction

LL-37 has no FDA-approved human dose for any indication. Despite extensive research on the peptide’s biology and ongoing clinical development for specific applications, no approved therapeutic exists. The dosing information available is a mix of clinical research doses, compounding pharmacy practice, and wellness forum recommendations.

This guide covers what clinical research has used, what wellness protocols typically recommend, the safety considerations, and the practical aspects of using LL-37 in a non-approved context.

The honest framing: anyone using LL-37 outside of formal clinical trials is doing so without controlled evidence supporting specific doses, schedules, or outcomes.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Doses Have Been Used in Clinical Research?

For topical LL-37 in dermatologic applications, concentrations of 100 micrograms per milliliter to several milligrams per milliliter have been studied in creams, solutions, and gels. Application frequency has varied from once to several times daily depending on the formulation and indication.

Quick Answer: Clinical research has used topical concentrations from 100 mcg/mL to several mg/mL

Inhaled LL-37 has been explored for cystic fibrosis-related infections and other respiratory applications. Doses have varied, with significant attention to formulation issues affecting aerosol delivery and lung deposition.

Systemic intravenous LL-37 in early clinical research has used variable doses, typically scaled from animal pharmacokinetic studies. The therapeutic window has been narrow due to dose-limiting toxicity at higher concentrations.

For comparison, animal studies have used systemic doses ranging from a few micrograms per kilogram to several milligrams per kilogram, with mechanism studies often using locally applied concentrations rather than systemic dosing.

What Subcutaneous Doses Do Wellness Protocols Use?

Compounded LL-37 for wellness use is typically supplied as lyophilized powder in vials containing 5 to 10 mg total content. Reconstituted with bacteriostatic water, this allows multiple doses per vial.

Typical wellness protocols use 100 to 500 micrograms subcutaneously per dose, administered daily, every other day, or several times per week. These doses are conventions rather than evidence-based recommendations.

For a 70 kg adult, 500 micrograms daily works out to roughly 7 micrograms per kilogram per day. This is much lower than systemic doses used in some clinical research but probably appropriate for wellness contexts where toxicity concerns matter and outcomes are subjective.

Higher doses have been used by some practitioners for specific infections or wound healing applications, but the dose-response relationship in humans hasn’t been characterized well enough to support specific recommendations.

How Is Oral LL-37 Used?

Oral LL-37 has significant bioavailability challenges. The peptide is degraded by gastric acid and proteases throughout the GI tract. Most LL-37 taken orally won’t reach systemic circulation intact.

Some products attempt enteric coating, lipid encapsulation, or other formulation tricks to improve bioavailability. The actual systemic absorption from these formulations is poorly characterized.

For local gut effects, oral LL-37 might have some activity at the gut mucosal surface before being degraded. This is theoretically relevant for gut infections or inflammation, but evidence-based dosing for these uses doesn’t exist.

If you’re considering oral LL-37, recognize that the dose-response relationship is essentially unknown and the products vary widely in quality and formulation.

Are There Topical Applications Worth Considering?

Topical LL-37 has more research foundation than systemic use. Chronic wound applications, particularly diabetic foot ulcers and chronic venous ulcers, have been studied with topical LL-37 formulations.

For skin infections, topical LL-37 has activity against bacteria including MRSA and might offer alternatives to topical antibiotics. Clinical development has been ongoing but no FDA-approved topical product is available as of 2026.

For acne, rosacea, or other inflammatory skin conditions, the complex LL-37 biology argues for caution. The peptide contributes to rosacea pathology in some cases, so topical application could theoretically worsen rather than help certain skin conditions.

Wellness use of topical LL-37 for skin appearance or anti-aging has minimal evidence base. The peptide is not a cosmeceutical with established efficacy for these purposes.

Should LL-37 Be Cycled?

Common wellness protocols suggest cycling LL-37, typically 4 to 8 weeks on followed by 2 to 4 weeks off. The stated rationales include preventing tolerance, limiting unknown long-term effects, and matching general peptide therapy conventions.

There is no published evidence that LL-37 produces tolerance with continued use. The cycling approach is precautionary rather than evidence-based.

For specific clinical applications like wound healing, continuous use through the healing process makes more sense than arbitrary cycling. For general wellness use, the case for cycling is weaker but also no evidence supports either continuous or cycled use.

Key Takeaway: Oral LL-37 has very limited bioavailability due to gastric and intestinal proteolysis

What About Combining LL-37 with Other Peptides?

Wellness protocols frequently combine LL-37 with BPC-157, TB-500, KPV, or other peptides marketed for related purposes. No controlled data supports specific combinations.

Theoretical interactions could occur between LL-37 and other immune-modulating peptides. The complexity of LL-37’s effects on immune function makes prediction of combination outcomes essentially impossible without controlled studies.

If you’re committed to peptide combinations, recognize that you’re stacking unknown quantities. Each additional peptide adds variables and potential interactions that haven’t been characterized.

What Safety Monitoring Makes Sense?

For wellness LL-37 use, reasonable monitoring includes:

Baseline assessment of why you’re using LL-37 and what you’d track to know if it’s working. Subjective wellness goals are harder to measure than specific clinical endpoints.

Watch for signs of autoimmune disease activity, particularly if you have any history of psoriasis, lupus, or related conditions. The autoimmune-promoting biology of LL-37 is a real concern in vulnerable populations.

Watch for unusual infections or wound healing problems that could suggest unexpected effects on immune function.

For patients with chronic conditions or on other medications, talk to your prescriber. LL-37 could theoretically interact with immune-modulating therapies in ways that aren’t characterized.

Are There Populations WHO Should Avoid LL-37?

Patients with autoimmune disease should be cautious or avoid LL-37 entirely. The peptide contributes to psoriasis, lupus, and other autoimmune disease pathology. Boosting LL-37 in these conditions could theoretically worsen disease.

Patients with rosacea should avoid topical LL-37 specifically. Dysregulated cathelicidin processing contributes to rosacea, and adding more substrate could exacerbate the condition.

Pregnant and breastfeeding women should avoid experimental peptides without proven safety profiles.

Patients with cancer or history of cancer should discuss with their oncologist. LL-37 has complex effects on cancer cells with both pro- and anti-tumor activities documented.

How Does This Fit with GLP-1 Therapy?

LL-37 isn’t typically combined with GLP-1 medications in wellness protocols, but the question comes up. No controlled data exists on this combination.

For someone on a GLP-1 medication considering LL-37 for immune support, the question is what specific health concern is being addressed. General “immune boosting” has weak evidence regardless of intervention. Specific health concerns warrant evidence-based evaluation rather than experimental peptide combinations.

TrimRx focuses on FDA-approved active ingredients in compounded GLP-1 medications. The evidence base for semaglutide and tirzepatide is substantial: STEP 1 (Wilding et al. 2021 NEJM) for semaglutide weight loss; SURMOUNT-1 (Jastreboff et al. 2022 NEJM) for tirzepatide weight loss; SELECT (Lincoff et al. 2023 NEJM) for cardiovascular benefit. The free assessment quiz and personalized treatment plans operate in this evidence-based space.

Adding experimental peptides like LL-37 outside this framework requires understanding that you’re moving away from evidence-based care.

Bottom line: LL-37 can be cytotoxic at high concentrations, complicating dose optimization

FAQ

What’s a Typical Starting Dose for Someone Trying LL-37?

There is no established safe starting dose. Wellness protocols often start at 100 micrograms subcutaneously and titrate up. This is convention, not evidence-based dosing.

Can You Take LL-37 with Food?

For subcutaneous administration, food doesn’t matter. For oral LL-37, food and gastric acid affect peptide stability, but the practical effect on absorption is poorly characterized.

How Do You Store LL-37?

Lyophilized peptide should be stored frozen. Once reconstituted with bacteriostatic water, store refrigerated and protected from light. Use within 14 to 30 days depending on the specific product.

What If You Have a Skin Reaction to LL-37 Injections?

Stop the injections and consult a healthcare provider. Hypersensitivity reactions to peptide therapeutics occur and can range from mild local reactions to systemic anaphylaxis.

Does LL-37 Interact with Antibiotics?

Theoretical interactions are possible since both target bacteria, but no clinical data addresses specific combinations. If you’re on prescription antibiotics, talk to whoever prescribed them about LL-37 use.

Can LL-37 Be Used Long-term Safely?

No long-term human safety data exists. The autoimmune-promoting biology argues for caution with chronic use. Limit duration of use until more data is available.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.